<DOC>
	<DOCNO>NCT00599196</DOCNO>
	<brief_summary>The objective open-label extension ass safety tolerability long-term treatment rotigotine patch subject early-stage idiopathic Parkinson 's disease</brief_summary>
	<brief_title>An Open-Label Extension Trial Assess Safety Long-Term Treatment Rotigotine Early-Stage Parkinson 's Disease</brief_title>
	<detailed_description>This open-label extension randomize , double-blind , placebo- ropinirole-controlled SP513 trial assess efficacy safety tolerability Rotigotine patch subject early-stage idiopathic Parkinson 's Disease</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subjects complete six month maintenance treatment SP513 doubleblind trial Subjects ongoing serious adverse event SP513 doubleblind trial assess related study medication</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>NeuproÂ®</keyword>
</DOC>